Oak Associates Ltd. OH Has $2.60 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Oak Associates Ltd. OH lowered its position in United Therapeutics Co. (NASDAQ:UTHR) by 2.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 7,365 shares of the biotechnology company’s stock after selling 150 shares during the period. Oak Associates Ltd. OH’s holdings in United Therapeutics were worth $2,599,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the fourth quarter valued at $25,000. Millstone Evans Group LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB boosted its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. Jones Financial Companies Lllp grew its stake in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in United Therapeutics in the fourth quarter worth approximately $131,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on UTHR shares. HC Wainwright restated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

Insiders Place Their Bets

In other news, Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares of the company’s stock, valued at $2,703,424. This represents a 22.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Dwek sold 4,000 shares of the stock in a transaction on Monday, April 7th. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00. Following the transaction, the director now owns 1,750 shares of the company’s stock, valued at $497,962.50. The trade was a 69.57 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 87,500 shares of company stock valued at $30,640,680. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $278.89 on Friday. The stock has a market cap of $12.53 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82. The firm’s 50-day simple moving average is $324.67 and its 200 day simple moving average is $351.68.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the company posted $4.36 earnings per share. As a group, analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.